| |
Study group
|
Control group
|
p-value
|
|---|
|
n = 257
|
n = 168
|
|---|
|
Sex n (%)
| | |
0.901
|
|
Female
|
153 (59.5)
|
99 (58.9)
| |
|
Male
|
104 (40.5)
|
69(41.1)
| |
|
Age (years) median (min–max)
|
65 (19–89)
|
65 (30–89)
|
0.864
|
|
Cancer, n (%)
| | |
< 0.001
|
|
Breast
|
60 (23.3)
|
67 (39.9)
| |
|
Colorectal
|
39 (15.2)
|
35 (20.8)
| |
|
Upper GI
|
40 (15.6)
|
20 (11.9)
| |
|
Urogenital
|
13 (5.1)
|
27 (16.1)
| |
|
Haematologic cancer
|
56 (21.8)
|
0 (0)
| |
|
Others
|
26 (10.1)
|
19 (11.3)
| |
|
Gyn
|
23 (8.9)
|
0 (0)
| |
|
Treatment strategy, n (%)
| | |
0.182
|
|
Adjuvant
|
147 (57.2)
|
107 (63.7)
| |
|
Palliative
|
110 (42.8)
|
61 (36.3)
| |
- GI gastrointestinal, Gyn gynaecological
